Prostate Cancer Diagnostics and Minimally Invasive Treatments Market
Prostate Cancer Diagnostics and Minimally Invasive Treatments Market
$4,750.00
This comprehensive medical market and technology report provides an overview and in-depth market analysis of selected next-generation prostate cancer diagnostics, biopsy, and minimally invasive treatments.
Publisher: Meddevicetracker
- Highlights
- Description
- Contents
Key Questions Answered
- What is the value of the prostate cancer diagnostics and minimally invasive treatments market? Expected growth?
- Estimated sales and growth by segment and region?
- Key market drivers and limiters?
- New products and innovations?
- Leading competitors?
- Estimate market share?
- Startups or emerging competitors?
- Trends & opportunities?
Overview
Over 1.4 million new cases of prostate cancer were recorded in 2020 worldwide, accounting for approximately 7.3% of all new cancer cases. There were an estimated 375,000 deaths from the disease in 2020, or 3.8% of cancer deaths worldwide. In 2020, combined sales of prostate cancer diagnostics and minimally invasive treatments totaled more than $1.4bn. The main drivers of the prostate cancer diagnostics and minimally invasive treatments market include the increasing incidence of prostate cancer worldwide, an expanding elderly demographic, improved early diagnosis guidelines, increasing patient awareness pertaining to prostate cancer, as well as technological advancements allowing more accurate and precise diagnosis and targeting of more aggressive types of cancer at an earlier stage. Factors that are anticipated to restrain market growth during the forecast period include the lack of population-based screening programs, country-specific reimbursement issues, increased regulatory oversight, and the high cost of some prostate cancer diagnostic and treatment technologies. This comprehensive medical market and technology report provides an overview and in-depth market analysis of selected next-generation prostate cancer diagnostics, biopsy, and minimally invasive treatments. For the purpose of this report, diagnostic technologies include in vitro diagnostics, liquid biopsy, and image-guided biopsy. Prostate cancer treatment options covered by this analysis include minimally invasive treatments such as robotic-assisted laparoscopic prostatectomy (RALP), radiation treatment, and ablation techniques. Drug treatments are not covered in this report. Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2020–25.
The report provides the following useful information
- an epidemiological overview of prostate cancer
- analysis of selected leading diagnostic and treatment products
- competitive analysis, including estimated market share and emerging competition
- insight into factors driving and limiting market growth
- estimated five-year market forecasts.
Table of Contents
Executive Summary ………………………………………………………………………. ES-1
i. Prostate cancer overview………………………………………………………………………………………ES-1
ii. Prostate cancer diagnostics and minimally invasive treatments market …………………….ES-1
a. Market drivers and limiters……………………………………………………………………….ES-6
b. Technology trends …………………………………………………………………………………..ES-6
c. Market leaders………………………………………………………………………………………..ES-7
d. Competitive strategies……………………………………………………………………………..ES-7
e. Emerging competition………………………………………………………………………………ES-7
iii. Methodology……………………………………………………………………………………………………..ES-7
iv. Bibliography ………………………………………………………………………………………………………ES-9
Exhibit ES-1: Prostate cancer diagnostic products, global market forecast, 2020–25 ………ES-3
Exhibit ES-2: Minimally invasive prostate cancer treatments, global market forecast, 2020–25…………………………………………………………………..ES-5
1. Prostate Cancer Overview……………………………………………………………..1-1
1.1 Staging……………………………………………………………………………………………………………… 1-1
1.2 Incidence: US, five major European markets, and Japan…………………………………………. 1-1
1.2.1 Impact of COVID-19 pandemic ……………………………………………………………… 1-2
1.3 Risk factors……………………………………………………………………………………………………….. 1-3
1.3.1 Genetics …………………………………………………………………………………………….. 1-3
1.4 Detection and diagnosis……………………………………………………………………………………… 1-4
1.4.1 PSA testing …………………………………………………………………………………………. 1-5
1.4.2 Screening……………………………………………………………………………………………. 1-6
1.4.3 Biopsy………………………………………………………………………………………………… 1-7
1.4.4 Molecular diagnostics and liquid biopsy……………………………………………….. 1-13
1.5 Prostate cancer treatment pathways…………………………………………………………………. 1-16
1.5.1 Treatment of localized prostate cancer………………………………………………… 1-17
1.5.2 Treatment of locally advanced prostate cancer…………………………………….. 1-18
1.5.3 Treatment of recurrent/progressive prostate cancer …………………………….. 1-18
1.5.4 Treatment of metastatic hormone-sensitive prostate cancer …………………. 1-18
1.5.5 Treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)……………………………. 1-18
1.5.6 Treatment of metastatic castration-resistant prostate cancer ………………… 1-19
1.5.7 Surgery …………………………………………………………………………………………….. 1-19
1.5.8 Radiation therapy ……………………………………………………………………………… 1-20
1.5.9 Hormonal therapy……………………………………………………………………………… 1-23
1.5.10 Biological treatments……………………………………………………………………….. 1-24
1.5.11 Chemotherapy ………………………………………………………………………………… 1-24
1.5.12 Vascular targeted photodynamic therapy …………………………………………… 1-24
1.5.13 Ablation and focal therapies……………………………………………………………… 1-25
1.5.14 Experimental treatments………………………………………………………………….. 1-29
1.6 Bibliography ……………………………………………………………………………………………………. 1-32
Exhibit 1-1: Estimated incident cases of prostate cancer, selected countries, 2020 and 2025………………………………………………………………… 1-2
Exhibit 1-2: Advantages and disadvantages of multiparametric MRI for prostate imaging 1-11
Exhibit 1-3: Advantages and disadvantages of liquid biopsy……………………………………….. 1-15
Exhibit 1-4: Surgical options for prostate cancer……………………………………………………….. 1-19
Exhibit 1-5: Advantages/disadvantages of cryotherapy for prostate cancer treatment….. 1-26
Exhibit 1-6: HIFU for prostate cancer using the transrectal approach ………………………….. 1-27
Exhibit 1-7: Advantages/disadvantages of HIFU for prostate cancer treatment ……………. 1-29
Exhibit 1-8: Advantages/disadvantages of irreversible electroporation for prostate cancer treatment…………………………………………………………………………………………………. 1-31
2. Prostate Cancer Diagnostics…………………………………………………………..2-1
2.1 PSA tests…………………………………………………………………………………………………………… 2-1
2.2 Molecular diagnostic and liquid biopsy products…………………………………………………… 2-2
2.2.1 Tests performed before biopsy……………………………………………………………… 2-2
2.2.2 Tests performed after biopsy ……………………………………………………………….. 2-5
2.2.3 Tests to guide therapy …………………………………………………………………………. 2-9
2.3 Biopsy guidance systems ………………………………………………………………………………….. 2-11
2.3.1 Transrectal ultrasound (TRUS)-guided needle biopsy systems ………………… 2-11
2.3.2 MRI-US fusion prostate biopsy systems ……………………………………………….. 2-11
2.3.3 In-bore MRI-guided biopsy systems …………………………………………………….. 2-15
2.3.4 Transperineal biopsy products/technologies ………………………………………… 2-15
2.4 Prostate cancer diagnostic products market……………………………………………………….. 2-16
2.4.1 Global market insights……………………………………………………………………….. 2-17
2.4.2 Market value…………………………………………………………………………………….. 2-17
2.4.3 Segment insights……………………………………………………………………………….. 2-19
2.4.4 Regional insights……………………………………………………………………………….. 2-23
2.4.5 Market trends…………………………………………………………………………………… 2-36
2.4.6 Market drivers and limiters ………………………………………………………………… 2-37
2.4.7 Market share…………………………………………………………………………………….. 2-38
2.5 Bibliography ……………………………………………………………………………………………………. 2-41
Exhibit 2-1: Selected molecular diagnostic/liquid biopsy products for use before biopsy ……. 5
Exhibit 2-2: Selected molecular diagnostic/liquid biopsy products for use after biopsy ………. 8
Exhibit 2-3: Selected molecular diagnostic/liquid biopsy products for prostate cancer therapy selection and monitoring………………………………………………………………………………..10
Exhibit 2-4: Selected commercially available MRI-US fusion biopsy systems for prostate cancer diagnosis ………………………………………………………………………………………………………13
Exhibit 2-5: Prostate cancer diagnostic products, combined market forecast, by product segment, 2020–25 …………………………………………………………………………………………18
Exhibit 2-6: Prostate cancer diagnostic products, US market forecast, 2020–25 ……………….24
Exhibit 2-7: Prostate cancer diagnostic products, 5 Euro market forecast, 2020–25 ………….27
Exhibit 2-8: Prostate cancer diagnostic products, Japan market forecast, 2020–25……………32
Exhibit 2-9: Prostate cancer diagnostic products, RoW market forecast, 2020–25…………….34
Exhibit 2-10: Prostate cancer diagnostic products market, share by supplier, 2020 …………..40
3. Minimally Invasive Prostate Cancer Treatments……………………………….. 3-1
3.1 Prostate cancer surgery ……………………………………………………………………………………… 3-1
3.1.1 Robotic-assisted laparoscopic prostatectomy (RALP) products…………………. 3-1
3.2 Prostate radiation therapy………………………………………………………………………………….. 3-5
3.2.1 External beam radiation therapy …………………………………………………………… 3-5
3.2.2 Brachytherapy…………………………………………………………………………………….. 3-6
3.2.3 Hydrogel spacers for radiotherapy ………………………………………………………. 3-13
3.3 Ablation of prostate cancer ………………………………………………………………………………. 3-14
3.3.1 Cryoablation……………………………………………………………………………………… 3-14
3.3.2 High-intensity focused ultrasound……………………………………………………….. 3-16
3.3.3 Irreversible electroporation (IRE) ………………………………………………………… 3-21
3.4 Minimally invasive prostate cancer treatments market………………………………………… 3-22
3.4.1 Market value…………………………………………………………………………………….. 3-23
3.4.2 Segment insights……………………………………………………………………………….. 3-25
3.4.3 Regional insights……………………………………………………………………………….. 3-27
3.4.4 Market trends…………………………………………………………………………………… 3-43
3.4.5 Market drivers and limiters ………………………………………………………………… 3-45
3.4.6 Market leaders………………………………………………………………………………….. 3-46
3.5 Bibliography ……………………………………………………………………………………………………. 3-49
Exhibit 3-1: Minimally invasive prostate cancer treatments, combined market forecast, by product segment, 2020–25…………………………………………………………………………. 3-24
Exhibit 3-2: Minimally invasive prostate cancer treatments, US market forecast, 2020–25 ……………………………………………………………………… 3-28
Exhibit 3-3: Minimally invasive prostate cancer treatments, 5 Euro market forecast, 2020–25 ………………………………………………………………… 3-32
Exhibit 3-4: Minimally invasive prostate cancer treatments, Japan market forecast, 2020–25 …………………………………………………………………. 3-37
Exhibit 3-5: Minimally invasive prostate cancer treatments, RoW market forecast, 2020–25…………………………………………………………………… 3-41
Exhibit 3-6: Minimally invasive prostate cancer treatments, forecast by region, 2020–25 ……………………………………………………………………….. 3-42
Exhibit 3-7: Minimally invasive prostate cancer treatments, share by supplier, 2020………………………………………………………………………………. 3-48
Appendix: Company Listing……………………………………………………………… A-1
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Dyslipidemia 
Sign up to the